OP20
Anti-c-Abl (Ab-3) Mouse mAb (24-21)
liquid, clone 24-21, Calbiochem®
Synonym(s):
Anti-p150, Anti-Abl
Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
NACRES:
NA.41
UNSPSC Code:
12352203
Product Name
Anti-c-Abl (Ab-3) Mouse mAb (24-21), liquid, clone 24-21, Calbiochem®
biological source
mouse
antibody form
purified antibody
antibody product type
primary antibodies
clone
24-21, monoclonal
form
liquid
contains
≤0.1% sodium azide as preservative
species reactivity
mouse, human
manufacturer/tradename
Calbiochem®
storage condition
do not freeze
dilution
(Immunoblotting (1-5 µg/mL)
Immunofluorescence
Immunoprecipitation (1-2 µg/sample)
Neutralization Studies (not recommended))
isotype
IgG1
shipped in
wet ice
storage temp.
2-8°C
target post-translational modification
unmodified
Quality Level
Gene Information
human ... ABL1(25)
Analysis Note
Positive Control
K562 (human bcr/abl), HL-60 (normal abl), and ANN-1 (murine abl) cells
K562 (human bcr/abl), HL-60 (normal abl), and ANN-1 (murine abl) cells
Application
Immunoblotting (1-5 µg/ml)
Immunofluorescence (see application references)
Immunoprecipitation (1-2 µg/sample)
Neutralization Studies (not recommended)
Immunofluorescence (see application references)
Immunoprecipitation (1-2 µg/sample)
Neutralization Studies (not recommended)
Disclaimer
Toxicity: Standard Handling (A)
General description
Anti-c-Abl (Ab-3), mouse monoclonal, clone 24-21, recognizes the ~145 kDa human and ~150 kDa mouse c-Abl. It is validated for Western blotting, immunofluorescence, and immunoprecipitation.
Purified mouse monoclonal antibody generated by immunizing BALB/c mice with the specified immunogen and fusing splenocytes with p.3U1 mouse myeloma cells (see application references). Recognizes the v-Abl, the ~145-150 kDa c-Abl, the ~210 kDa Bcr-Abl (CML), and the ~190 kDa Bcr-Abl (ALL) proteins.
Recognizes the ~145 kDa human c-Abl, the ~150 kDa mouse c-Abl, v-Abl, and the Bcr/Abl translocation products in ALL (~190 kDa) and CML (~210 kDa). Does not inhibit protein tyrosine kinase activity.Antibody Target Gene Symbol: ABL1 Target Synonym: ABL, AI325092, bcr/abl, C-ABL, C-ABL 1B, CABL1, E430008G22Rik, JTK7, MGC117749, p145Abl, p150, v-abl Entrez Gene Name: c-abl oncogene 1, receptor tyrosine kinase Hu Entrez ID: 25 (Related Antibodies: PK1006PK1013OP19) Mu Entrez ID: 11350 Rat Entrez ID: 311860
Immunogen
a recombinant protein consisting of the carboxyl region of v-abl protein fused to TrpE
Other Notes
Does not inhibit protein tyrosine kinase activity. Detects human c-Abl (145 kDa), mouse c-Abl (150 kDa), v-Abl, and the Bcr/Abl translocation products in ALL (~210 kDa) and CML (~190 kDa). HL-60 and NIH3T3 cells contain normal, non-rearranged protein. Antibody should be titrated for optimal results in individual sample types.
Wiedemann, L.M., et al. 1988. Blood71, 349.
Stam, K., et al. 1985. N. Engl. J. Med.313, 1429.
Konopka, J.B., et al. 1984. Cell37, 1035.
Prywes, R., et al. 1983. Cell34, 569.
de Klein, A., et al. 1982. Nature300, 765.
Reynolds, F.H., Jr., et al. 1980. J. Virol.36, 374.
Reynolds, F.H., Jr., et al. 1978. Proc. Natl. Acad. Sci. USA75, 3974.
Witte, O.N., et al. 1978. Proc. Natl. Acad. Sci. USA75, 2488.
Abelson, H.T. and Rabstein, L.S. 1970. Cancer Res.30, 2213.
Stam, K., et al. 1985. N. Engl. J. Med.313, 1429.
Konopka, J.B., et al. 1984. Cell37, 1035.
Prywes, R., et al. 1983. Cell34, 569.
de Klein, A., et al. 1982. Nature300, 765.
Reynolds, F.H., Jr., et al. 1980. J. Virol.36, 374.
Reynolds, F.H., Jr., et al. 1978. Proc. Natl. Acad. Sci. USA75, 3974.
Witte, O.N., et al. 1978. Proc. Natl. Acad. Sci. USA75, 2488.
Abelson, H.T. and Rabstein, L.S. 1970. Cancer Res.30, 2213.
Packaging
Please refer to vial label for lot-specific concentration.
Physical form
In 0.05 M sodium phosphate buffer, 0.2% gelatin, pH 7.5.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Not finding the right product?
Try our Product Selector Tool.
wgk
nwg
Storage Class
10 - Combustible liquids
flash_point_f
Not applicable
flash_point_c
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Alexander J M Blakes et al.
European journal of human genetics : EJHG, 29(4), 593-603 (2020-11-24)
ABL1 is a proto-oncogene encoding a nonreceptor tyrosine kinase, best known in the somatic BCR-ABL fusion gene associated with chronic myeloid leukaemia. Recently, germline missense variants in ABL1 have been found to cause an autosomal dominant developmental syndrome with congenital
Cong Fang et al.
Cancer research, 70(21), 8299-8308 (2010-09-15)
Oncogenic kinase activity and the resulting aberrant growth and survival signaling are a common driving force of cancer. Accordingly, many successful molecularly targeted anticancer therapeutics are directed at inhibiting kinase activity. To assess kinase activity in minute patient samples, we
Shigeru Matsumura et al.
Nature communications, 7, ncomms11858-ncomms11858 (2016-06-14)
Despite theoretical and physical studies implying that cell-extracellular matrix adhesion geometry governs the orientation of the cell division axis, the molecular mechanisms that translate interphase adhesion geometry to the mitotic spindle orientation remain elusive. Here, we show that the cellular
Tamjeed Saleh et al.
Nature structural & molecular biology, 24(11), 893-901 (2017-09-26)
The activity of protein kinases is often regulated in an intramolecular fashion by signaling domains, which feature several phosphorylation or protein-docking sites. How kinases integrate such distinct binding and signaling events to regulate their activities is unclear, especially in quantitative
Jennifer Asmussen et al.
Cancer discovery, 4(2), 200-215 (2013-12-24)
The clinical experience with BCR-ABL tyrosine kinase inhibitors (TKI) for the treatment of chronic myelogenous leukemia (CML) provides compelling evidence for oncogene addiction. Yet, the molecular basis of oncogene addiction remains elusive. Through unbiased quantitative phosphoproteomic analyses of CML cells
Related Content
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service